SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

BLOCKBUSTER ‘Ozempic-style’ fat jabs could increase the risk of depression and suicidal thoughts, experts have warned. The ...

Blockbuster weight loss drugs like Ozempic could leave users at a higher risk of depression and suicidal thoughts, a ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

US President Donald Trump’s recent weight loss has become the talk of the town after his recent medical exam revealed a ...

GLP-1 receptor agonists such as semaglutide and tirzepatide have proven to be highly effective in supporting weight loss by regulating appetite and metabolism. These medications work by mimicking ...

GP leaders will vote on demanding payment for any additional work transferred to general practice from secondary care.

But, like all medications, there are side effects to using both Ozempic and Mounjaro with several celebrities sharing their ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between ...

The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.